Cracking Cancer Podcast

Siblings are often the "forgotten mourners" in a cancer journey. They act as the family’s voice of reason while carrying their own silent grief. We must give siblings the stage to share their experience. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/uPOwkP9ia6k

The "uncomfortable truth" of cancer is balancing the fear of recurrence with the beauty of community support. Meal trains and house cleaners aren't just help—they are anchors of love. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/uPOwkP9ia6k

The learning curve of a cancer diagnosis is "insane." For some, that means diving into research papers and scan data immediately. Supporting a loved one means evolving from "naive" to a "high-knowledge" advocate. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/uPOwkP9ia6k

The gap between clinical success and patient hope is real. A 3-month survival gain gets a standing ovation from scientists, but for a family, it's a reminder of the battle's gravity. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

Pharma-patient dialogue is vital. At IASLC, J&J reps shared the COCOON protocol to help manage Amivantamab skin toxicity, turning fear into an actionable plan. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

Patient Advocacy Groups act as "intelligence bridges," bringing research from global conferences back to local communities. In rare cancers, your group will often hear about new approvals before your doctor does. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

The "knowledge gap" between academic centers and community hospitals is real when the situations are rare. Patients in rural areas must advocate for NGS testing and clinical trial awareness to bridge this disparity. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

ASCO is a 30,000-person "firehose" of data. For patients, the Poster Halls are gold mines for early-phase trial results and new drug leads. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

For niche mutations like Exon 20, patients often know more than 90% of oncologists. Living with a specific subtype makes you a specialized researcher. Don't be afraid to lead the conversation. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

Crashing medical conferences for clinical trial access is a bold move. While the jargon is a barrier, being "in the room" builds vital advocacy networks. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/e7ycOBOl7co

Patients and loved ones often wonder if attending national cancer meetings can give them a cutting-edge advantage. In this episode, Dr. Concannon and patient advocate ⁦@maxdoppelt⁩ discuss the pros and cons of patients attending major conferences. podcasts.apple.com/us/podcast/the…

We are currently in a "discovery phase" for blood-based monitoring. These tools are great inventions, but we lack long-term data on their "added value". Ask: "If this is positive, what is the actionable next step?" Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

Is catching a recurrence one month early actually beneficial? Before adding tests, ask your doctor: "What will we do if this is positive?" and "Will catching this sooner change my treatment outcome?" Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

Liquid biopsies look for a tumors signs in the blood, often detecting mutations at levels as low as 0.1%. While the tech is precise, clinicians are still learning how to interpret these results. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

Being at the "cutting edge" of oncology means we lack data on the risks of new tests. Patient advocacy tends to frame every new tool as purely positive, but we need more talks on the potential burdens. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

A false positive led to months of trauma, PET scans, and brain MRIs that could have been avoided by sticking to standard monitoring. Sometimes, the most important medical decision is saying no to unnecessary testing. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

The irony oncology: extra testing meant to alleviate anxiety often worsens it. For slow-growing cancers, the medical outcome rarely changes between a 3-month and 6-month scan. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

Survivorship is a trade-off between physical security and mental peace. Catching a recurrence early is vital, but the frequent testing required to do so creates a cycle that can rob patients of their normalcy. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk

If you haven't listened to @DRCamidge speech at 2026 TTLC, watch it now: youtube.com/watch?v=cnh579…

For early-stage cancer patients, blood tests can lack the data needed for accuracy, leading to false positives. Seeking a second opinion is often necessary for clarity, but it comes with significant scanxiety. Support ➡️ Giving.CU.EDU/CrackingCancer 🔗youtu.be/wy2PFHm3fSk